Trade Q32 Bio Inc - QTTB CFD

Homology Medicines Company profile

About Homology Medicines Inc

Homology Medicines, Inc. is a clinical-stage genetic medicines company. The Company focuses on patients suffering from rare genetic diseases by curing the underlying cause of the disease. Its platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs), to deliver single administration genetic medicines in vivo either through gene therapy or nuclease-free gene editing across a range of genetic disorders. Its various set of AAVHSCs allows it to target, via a single injection, a range of disease-relevant tissues, including the liver, central nervous system (CNS), peripheral nervous system (PNS), bone marrow, muscle and eye. Its lead product candidate, HMI-102, is a gene therapy for the treatment of adults with phenylketonuria (PKU). Its other gene therapy product development candidates for the treatment of lysosomal storage diseases are HMI-203, for the treatment of mucopolysaccharidosis type II (MPS II) and HMI-202.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Homology Medicines Inc revenues increased from $1.7M to $33.2M. Net loss decreased 37% to $62.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development - Balancing val decrease of 13% to $63.1M (expense), General and administrative - Balancing decrease of 1% to $19.8M (expense).